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Metaplastic breast cancer with rapidly progressive 
recurrence in a young woman: case report and review 
of the literature
Jerzy W. Mituś1,2, Beata Sas-Korczyńska3, Anna Kruczak4, Marek Jasiówka5, Janusz Ryś4
Metaplastic breast carcinoma (MpBC) is a rare neoplasia. It accounts 
for less than 1% of all breast carcinomas (BC), and the incidence of this 
type of cancer has risen since 2000 (the World Health Organization 
(WHO) recognized MpBC as a distinct type of breast cancer). It is made 
up of heterogeneous subgroups of malignant tumors built of neoplastic 
epithelium differentiated into squamous cells and/or mesenchymal-look-
ing elements [1–4]. The most common histopathological subtypes are 
squamous cell carcinoma and metaplastic carcinoma with mesenchymal 
differentiation [5–9]. Over 90% of MpBCs are ER, PR, and HER2 negative 
(“triple negative”), contrary to intraductal carcinomas, which are triple 
negative in 18% of cases [8, 10–14]. The mean age of MpBC patients is 
about 50 years of age [7, 15–17]. In most studied cases a diagnosis may 
not be achieved by use of core needle biopsies, and histological examina-
tion of the surgical specimen allows for the definitive diagnosis of MpBC 
[9, 18, 19]. There is no standard treatment regimen specific for MpBC, 
which is characterized by a poor prognosis. We present here a case of 
rapidly progressive recurrence of MpBC.
We present a  case of a 22-year-old woman, with a negative family 
history of BC. She came to our clinic with right breast enlargement and 
had experienced pain in the preceding 3 months. Physical examination 
showed a  tumor filling the right breast, with a maximum diameter of 
20 cm. There was no skin or nipple retraction and no axillary lymphade-
nopathy. In ultrasound examination, the lesion appeared as a solid-liquid 
tumor with sharp borders, 20 cm in a diameter. The axillary lymph nodes 
were not affected. It was classified as BI-RADS category 4b. By means 
of a  fine needle aspiration biopsy, 210 ml of serous-bloody fluid was 
obtained. A  core needle biopsy was performed and histological exam-
inations showed breast tissue with non-specific, chronic inflammation 
around the ducts and lobules with no evidence of a neoplasm. 
The patient underwent a  lumpectomy during which the nipple and 
part of the pectoralis major muscle were removed. A  histological ex-
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amination showed macroscopically a 20 × 18 cm 
encapsulated tumor infiltrating the muscle with 
central necrosis. 
Microscopically, the tumor was well circum-
scribed and consisted of both spindle and poor-
ly differentiated epithelial cells. The spindle cells 
formed long parallel fascicles (Figure 1) separat-
ed by collagen bands and deposits of amorphous 
extracellular material, which focally presented 
an osteoid-like appearance (Figure 2). The poorly 
differentiated epithelial cells created a  solid tex-
ture (Figure 3) with extensive foci of necrosis and 
hemorrhages. Both spindle and epithelial cells are 
characterized by a high nuclear grade and high mi-
totic activity. 
Immunohistochemical staining revealed that 
epithelial cells stained focally for cytokeratins 
CAM5.2 (Figure 4), whereas the spindle cell compo-
nent reacted strongly to CD10, desmin (Figure 5), 
and P53 protein. Both constituents were char-
acterized by an intensive, membranous reaction 
to EGFR protein (Figure 6) and were negative for 
Figure 1. Spindle cell component of the tumor; 
high nuclear grade, numerous mitoses
Figure 2. Osteoid formation
Figure 3. Poorly differentiated epithelial compo-
nent of the tumor
Figure 4. Anti-cytokeratin CAM5.2 positivity in the 
poorly differentiated epithelial tumor component
Figure 5. Positive reaction against desmin in the 
spindle cell component of the tumor
Figure 6. Diffuse membranous reaction to epider-
mal growth factor receptor (EGFR)
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steroid receptors (ER, PR) and HER2 protein. The 
Ki-67 index ranged from 89% (in the spindle cell 
component) to 91% (epithelial cells). According 
to the WHO 2012 Classification of Tumors of the 
Breast, the tumor was classified as breast carcino-
ma with leiomyosarcomatous and osseous meta-
plasia (metaplastic carcinoma) high grade (G3) [1]. 
Margins on all sides were tumor free. The post-
operative staging was assessed as pT3 pN0 pM0 
(stage IIB).
On 39 day following the operation (22 days 
after the last follow-up examination), the patient 
came for histopathology results, and a  physical 
examination revealed two lesions above the sur-
gical scar. An ultrasound examination showed the 
lesions to be 5.9 cm and 4.7 cm in diameter. The 
results of the fine needle aspiration biopsy and 
core biopsy confirmed the recurrence of the breast 
tumor. The lesions had almost doubled their di-
ameter in 10 days. A  computed tomography ex-
amination (CT) showed two tumors located in 
the right breast. Their maximum diameters were 
7.7 cm and 6.7 cm. The CT scan did not show any 
other pathology. 
The patient’s tumor was excised 2 months af-
ter the primary operation followed by a  Halsted 
reoperation of the right breast with stage I axillary 
lymph node dissection. A histological examination 
confirmed that the relapsed metaplastic breast 
carcinoma had been removed with a  thin tumor 
margin diameter of 1  mm on the pectoral side. 
The lymph nodes appeared normal. 
The patient was qualified for adjuvant chemo-
therapy comprising doxorubicin and cyclophos-
phamide. After the first chemotherapy cycle she 
received radiotherapy combined with hyperther-
mia. This decision was made on the grounds of 
dynamics of the chest wall recurrence in order to 
control the local process. Radiotherapy was carried 
out in the form of external radiation using mixed 
photon/electron beams generated in a  linear ac-
celerator. It was planned using a computer-aided 
therapy planning system. The beam energy was 
individually adjusted in consideration of the pa-
tient’s anatomical parameters. The planning tar-
get volume (PTV) included the chest wall and re-
gional lymph nodes with 1 cm margin. The total 
dose given to the PTV was 50 Gy in 25 fractions. 
Local hyperthermia was applied using the BSD-
500 system emitting electromagnetic radiation of 
915 MHz and 35 W in order to obtain a therapeu-
tic temperature in the range of 40–41°C. The pa-
tient was submitted to local hyperthermia 3 times 
a week (every second day) for 60 min immediately 
before each radiotherapy session. The area cov-
ered by hyperthermia involved the recurrence with 
an adequate margin. After the local treatment, the 
patient developed G3-skin reaction. 
Following radiotherapy, chemotherapy was con-
tinued for a total of 4 cycles with good tolerance. 
The patient remains under clinical observation. 
Table I  presents detailed clinical and pathologi-
cal characteristics of the patient and therapeutic 
choices.
Recent studies show that MpBC has a  worse 
prognosis and a  higher risk of recurrence than 
similar stage invasive ductal carcinoma (IDC) of 
no special type [11, 20, 21]. Comparing patients 
with MpBC and triple negative IDC, MpBC has 
a  lower survival rate, worse disease-free survival 
(DFS) (5-year DFS rate 39–56% vs. 60.3–77%) and 
a worse overall survival (OS) rate (5-year OS rate 
44–54.5% vs. 73.3–78%) [2, 10, 13, 20, 22]. There 
are a few hypotheses that stress the pathogenesis 
of MpBC, but none of them is accepted in the liter-
ature as the main cause of MpBC, and the cellular 
origin of MpBC is not yet clear [3, 4].
Our patient developed early (during 2 months) 
and rapidly progressive recurrence of the disease, 
as was confirmed by the clinical observation and 
the results of molecular tests. Hyperthermia was 
administered in combination with radiotherapy be-
Table I. Patient characteristics
Clinical 22-year old women. T3N0M0, BI-RADS 4b, 20 cm solid-liquid tumor, sharp borders
Surgery Lumpectomy (due to lack of preoperative histopatological conformation)
Pathological Metaplastic carcinoma, G3 (leiomyosarcomatous and osseous metaplasia).  
ER, PR, HER2 negative. pT3pN0pM0 
Clinical Chest wall recurrence 
Surgery Halsted reoperation + stage I axillary lymph nodes dissection
Postoperative staging pT4a pN0 pM0 
Adjuvant chemotherapy 1 course (doxorubicin and cyclophosphamide)
Radiotherapy Radiotherapy (50 Gy, 25 fractions) with hyperthermia (BSD-500 system, 915 MHz and 
35 Watt) 3 times in a week 
Adjuvant chemotherapy 3 courses (doxorubicin and cyclophosphamide)
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cause of previous experience with this treatment 
in dealing with inoperable or non-radically operable 
chest wall recurrence of breast cancer [23].
This variant of BC is very rare, which is why only 
small groups of patients are presented in the lit-
erature. The rarity of the disease makes it impos-
sible to conduct studies focused on this patient 
population. When comparing MpBC with breast 
adenocarcinomas, the tumor size is usually larger 
and the axillary lymph node metastases are less 
common in MpBC patients (22% in MpBC vs. 34% 
in IDC) [13, 16, 22]. Hormone and HER2 receptor 
positivity rates are also lower in MpBC [2, 13, 15, 
24]. According to the literature, the cancer cells are 
positive for p63 in more than 90% of MpBCs, so 
this marker may be useful in differential diagnosis 
with other spindle and mesenchymal tumors [12, 
25]. A Ki-67 index higher than 30% is observed in 
50% of MpBC cases compared with 81% observed 
in patients with invasive ductal carcinomas [2, 20, 
22]. EGFR overexpression is involved in 80% of 
MpBC cases, and p53 overexpression can be ob-
served in 32–71% of cases of MpBC [26–29]. 
In reviewed studies lung and bone metastases 
were found to be more frequent than lymphatic 
spread [6, 17]. This behavior of MpBC resembles 
that of sarcomas. Luini et al. reported 3 locally re-
current and 8 lung and bone metastatic patients in 
their 37 MpBC series [2]. The main distant meta-
static sites are the lungs, bone and the brain [2, 7, 8, 
15]. The literature shows this histologic subtype of 
BC to be chemoresistant. In a high portion of cases 
chemotherapy is used as adjuvant systemic treat-
ment [15, 21, 24]. However, new chemotherapeutic 
drugs should be considered when treating meta-
plastic subtypes to overcome resistance to cytotoxic 
agents. In addition to MpBC chemoresistance, most 
of them are hormone receptor negative and hor-
mone therapy is unnecessary [18, 21, 24, 29].
In conclusion, because of the rarity of the disease 
and the variety of histological subtypes that exist, 
the opportunities for conducting studies on this pa-
tient population are limited. Therefore the role of 
radiotherapy and chemotherapy is not yet clearly 
established, and surgical treatment is often the only 
choice available. Hormone therapy is unnecessary. 
Early diagnosis and surgical treatment are crucial to 
achieve an optimal outcome in patients with MpBC. 
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